In this scope, phase II clinical trials performed in patients with recent-onset T1DM using anti-CD3 monoclonal antibodies that suppress the immune system showed significant preservation of β-cell function for at least 24 months and to decrease insulin requirements [2]. Here, INS is linked to type 1 diabetes mellitus.